Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.9 USD | +2.27% | +5.84% | +17.70% |
May. 21 | Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing | MT |
May. 20 | ANI Pharmaceuticals Launches Kionex Suspension | MT |
Financials (USD)
Sales 2024 * | 539M | Sales 2025 * | 577M | Capitalization | 1.26B |
---|---|---|---|---|---|
Net income 2024 * | 33M | Net income 2025 * | 41M | EV / Sales 2024 * | 2.37 x |
Net Debt 2024 * | 20.98M | Net cash position 2025 * | 44.87M | EV / Sales 2025 * | 2.11 x |
P/E ratio 2024 * |
41.4
x | P/E ratio 2025 * |
27
x | Employees | 642 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.44% |
Latest transcript on ANI Pharmaceuticals, Inc.
1 day | +2.27% | ||
1 week | +5.84% | ||
1 month | -1.67% | ||
3 months | -4.09% | ||
6 months | +30.30% | ||
Current year | +17.70% |
Managers | Title | Age | Since |
---|---|---|---|
Nikhil Lalwani
CEO | Chief Executive Officer | 46 | 20-09-07 |
Stephen Carey
DFI | Director of Finance/CFO | 53 | 16-05-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Haughey
BRD | Director/Board Member | 60 | 18-04-30 |
Antonio Pera
BRD | Director/Board Member | 66 | 20-08-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 64.9 | +2.27% | 175,113 |
24-05-30 | 63.46 | +0.60% | 70,225 |
24-05-29 | 63.08 | -0.24% | 154,145 |
24-05-28 | 63.23 | +3.11% | 158,208 |
24-05-24 | 61.32 | +1.59% | 94,234 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.70% | 1.26B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- ANIP Stock